Screener
Veradermics MANE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Veradermics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Veradermics’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 5:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001827635-26-000019
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Income tax benefit | — | — |
| Net loss | $(27,232) | $(12,400) |
| Net loss attributable to common stock | $(30,011) | $(14,582) |
| Net loss per share of common stock, basic and diluted | $(1.32) | $(19.79) |
| Weighted average common stock outstanding, basic and diluted | 22,704,124 | 736,933 |
| Other comprehensive loss: | ||
| Net unrealized losses on marketable securities | (584) | — |
| Total other comprehensive loss | (584) | — |
Item 1. Condensed Consolidated Financial Statements (
FAQ
- What is Veradermics's EPS (diluted)?
- Veradermics (MANE) reported EPS (diluted) of -$1.32 in Q1 2026.
- How has Veradermics's EPS (diluted) changed year-over-year?
- Veradermics's EPS (diluted) increased by 93.3% year-over-year, from -$19.79 to -$1.32.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Veradermics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude